This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- In vivo Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity Antibodies
- Transport Cocktails for Cancer Therapeutics
- Mechanistically Weighted Metric to Predict In Vivo Antibody-Receptor Occupancy: An Analytical Approach
- Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
- Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics
- Valency of HER2 Targeting Antibodies Influences Tumor Cell Internalization and Penetration
- Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy
- Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
- Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy
- TAG-72-Targeted {alpha}-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody
- Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
- Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
- Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer
- Penetrating the Barriers to Successful {alpha}-Radioimmunotherapy
- Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin-Antibody Conjugate
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- Mechanistic considerations for the use of monoclonal antibodies for cancer therapy
- The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model
- Primer on tumor immunology and cancer immunotherapy
- Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors
- Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
- Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4
- Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
- Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
- Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma
- Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size
- PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models
- Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids
- Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
- Predicting Response to Radioimmunotherapy from the Tumor Microenvironment of Colorectal Carcinomas
- Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule
- PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5: EFFECTS ON TUMOR TARGETING
- Radioimmunotherapy Against the Tumor Vasculature: A New Target?
- Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens
- Effect of Inhibition of Vascular Endothelial Growth Factor Signaling on Distribution of Extravasated Antibodies in Tumors
- The Direct Route May Not Be the Best Way to Home
- High Affinity Restricts the Localization and Tumor Penetration of Single-Chain Fv Antibody Molecules
- Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591)
- Safety and Biodistribution of 99mTechnetium-labeled Anti-CD44v6 Monoclonal Antibody BIWA 1 in Head and Neck Cancer Patients
- Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3
- Kinetic Analysis of the Disposition of MRK16, an Anti-P-glycoprotein Monoclonal Antibody, in Tumors: Comparison Between in Vitro and in Vivo Disposition